Consistently, they reported that knockout of hepatic Surf4 using CRISPR-Cas9 significantly reduced plasma levels of cholesterol and TGs and reduced the development of atherosclerosis in a mouse model of hypercholesterolemia induced by overexpressing PCSK9. This evidence concerns the gene SURF4 and familial hypercholesterolemia.